AAPL333.74+0.48 (+0.14%) ▲|ABBV254.49+0.10 (+0.04%) ▲|ABT100.68+1.85 (+1.87%) ▲|ACN143.57-1.04 (-0.72%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.06+1.14 (+0.67%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.35-6.22 (-1.72%) ▼|BA214.03-0.31 (-0.14%) ▼|BAC61.27-0.22 (-0.36%) ▼|BKNG181.68-2.93 (-1.59%) ▼|BLK1,072.20-14.85 (-1.37%) ▼|BMY60.74+0.23 (+0.38%) ▲|BNY157.13-3.73 (-2.32%) ▼|BRK-B490.91-2.21 (-0.45%) ▼|C129.36-2.35 (-1.78%) ▼|CAT880.28+3.11 (+0.35%) ▲|CL92.98-1.09 (-1.16%) ▼|CMCSA23.79-0.31 (-1.29%) ▼|COF208.03-3.90 (-1.84%) ▼|COP114.71+1.87 (+1.66%) ▲|COST940.87-4.70 (-0.50%) ▼|CRM170.77-1.91 (-1.11%) ▼|CSCO111.94+2.28 (+2.08%) ▲|CVS107.47+0.97 (+0.91%) ▲|CVX187.38+3.52 (+1.91%) ▲|DE597.24-1.73 (-0.29%) ▼|DHR203.83-1.18 (-0.58%) ▼|DIS97.67-2.04 (-2.05%) ▼|DUK125.01-1.10 (-0.87%) ▼|EMR139.54+0.46 (+0.33%) ▲|FDX312.98-5.22 (-1.64%) ▼|GD368.58-0.24 (-0.07%) ▼|GE348.83+3.10 (+0.90%) ▲|GEV1,057.84+21.62 (+2.09%) ▲|GILD134.28-2.02 (-1.48%) ▼|GM76.07-1.65 (-2.12%) ▼|GOOG346.12-7.69 (-2.17%) ▼|GOOGL346.77-7.69 (-2.17%) ▼|GS1,065.22-30.24 (-2.76%) ▼|HD338.87-9.15 (-2.63%) ▼|HON225.02-1.31 (-0.58%) ▼|IBM212.67-6.38 (-2.91%) ▼|INTC95.04-1.94 (-2.00%) ▼|INTU291.09-3.70 (-1.26%) ▼|ISRG345.42-56.91 (-14.15%) ▼|JNJ253.04+3.07 (+1.23%) ▲|JPM341.10-2.05 (-0.60%) ▼|KO81.56-3.36 (-3.96%) ▼|LIN513.22-7.52 (-1.44%) ▼|LLY1,179.11+9.94 (+0.85%) ▲|LMT508.77-4.75 (-0.93%) ▼|LOW208.73-7.43 (-3.44%) ▼|LRCX313.30-7.66 (-2.39%) ▼|MA543.60-7.94 (-1.44%) ▼|MCD267.71-5.75 (-2.10%) ▼|MDLZ61.00-0.42 (-0.68%) ▼|MDT83.20-0.36 (-0.43%) ▼|META646.01-18.53 (-2.79%) ▼|MMM159.84-1.93 (-1.19%) ▼|MO74.21+1.18 (+1.62%) ▲|MRK127.50-0.13 (-0.10%) ▼|MS215.50-2.87 (-1.31%) ▼|MSFT393.82-7.28 (-1.82%) ▼|MU848.95-4.25 (-0.50%) ▼|NEE88.80-0.55 (-0.62%) ▼|NFLX68.95-5.40 (-7.26%) ▼|NKE43.76-0.81 (-1.82%) ▼|NOW103.24-0.77 (-0.74%) ▼|NVDA202.81-4.59 (-2.21%) ▼|ORCL126.41+2.20 (+1.77%) ▲|PEP137.12-2.31 (-1.66%) ▼|PFE25.05-0.09 (-0.36%) ▼|PG149.98-1.52 (-1.00%) ▼|PLTR132.38-2.06 (-1.53%) ▼|PM192.98+3.14 (+1.65%) ▲|QCOM171.78+1.11 (+0.65%) ▲|RTX193.51-0.85 (-0.44%) ▼|SBUX105.49-2.88 (-2.66%) ▼|SCHW101.56-1.24 (-1.21%) ▼|SO95.30-0.77 (-0.80%) ▼|SPG228.70+0.21 (+0.09%) ▲|T21.81-0.17 (-0.77%) ▼|TMO532.48-10.71 (-1.97%) ▼|TMUS192.43-0.42 (-0.22%) ▼|TSLA380.84-10.22 (-2.61%) ▼|TXN284.02-7.20 (-2.47%) ▼|UBER72.46-1.58 (-2.13%) ▼|UNH426.09+2.71 (+0.64%) ▲|UNP301.75+2.33 (+0.78%) ▲|UPS117.72+0.54 (+0.46%) ▲|USB63.14-0.87 (-1.36%) ▼|V358.56-6.58 (-1.80%) ▼|VZ43.59-0.29 (-0.66%) ▼|WFC87.51-0.56 (-0.64%) ▼|WMT114.24-0.71 (-0.62%) ▼|XOM147.36+1.41 (+0.97%) ▲|AAPL333.74+0.48 (+0.14%) ▲|ABBV254.49+0.10 (+0.04%) ▲|ABT100.68+1.85 (+1.87%) ▲|ACN143.57-1.04 (-0.72%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.06+1.14 (+0.67%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.35-6.22 (-1.72%) ▼|BA214.03-0.31 (-0.14%) ▼|BAC61.27-0.22 (-0.36%) ▼|BKNG181.68-2.93 (-1.59%) ▼|BLK1,072.20-14.85 (-1.37%) ▼|BMY60.74+0.23 (+0.38%) ▲|BNY157.13-3.73 (-2.32%) ▼|BRK-B490.91-2.21 (-0.45%) ▼|C129.36-2.35 (-1.78%) ▼|CAT880.28+3.11 (+0.35%) ▲|CL92.98-1.09 (-1.16%) ▼|CMCSA23.79-0.31 (-1.29%) ▼|COF208.03-3.90 (-1.84%) ▼|COP114.71+1.87 (+1.66%) ▲|COST940.87-4.70 (-0.50%) ▼|CRM170.77-1.91 (-1.11%) ▼|CSCO111.94+2.28 (+2.08%) ▲|CVS107.47+0.97 (+0.91%) ▲|CVX187.38+3.52 (+1.91%) ▲|DE597.24-1.73 (-0.29%) ▼|DHR203.83-1.18 (-0.58%) ▼|DIS97.67-2.04 (-2.05%) ▼|DUK125.01-1.10 (-0.87%) ▼|EMR139.54+0.46 (+0.33%) ▲|FDX312.98-5.22 (-1.64%) ▼|GD368.58-0.24 (-0.07%) ▼|GE348.83+3.10 (+0.90%) ▲|GEV1,057.84+21.62 (+2.09%) ▲|GILD134.28-2.02 (-1.48%) ▼|GM76.07-1.65 (-2.12%) ▼|GOOG346.12-7.69 (-2.17%) ▼|GOOGL346.77-7.69 (-2.17%) ▼|GS1,065.22-30.24 (-2.76%) ▼|HD338.87-9.15 (-2.63%) ▼|HON225.02-1.31 (-0.58%) ▼|IBM212.67-6.38 (-2.91%) ▼|INTC95.04-1.94 (-2.00%) ▼|INTU291.09-3.70 (-1.26%) ▼|ISRG345.42-56.91 (-14.15%) ▼|JNJ253.04+3.07 (+1.23%) ▲|JPM341.10-2.05 (-0.60%) ▼|KO81.56-3.36 (-3.96%) ▼|LIN513.22-7.52 (-1.44%) ▼|LLY1,179.11+9.94 (+0.85%) ▲|LMT508.77-4.75 (-0.93%) ▼|LOW208.73-7.43 (-3.44%) ▼|LRCX313.30-7.66 (-2.39%) ▼|MA543.60-7.94 (-1.44%) ▼|MCD267.71-5.75 (-2.10%) ▼|MDLZ61.00-0.42 (-0.68%) ▼|MDT83.20-0.36 (-0.43%) ▼|META646.01-18.53 (-2.79%) ▼|MMM159.84-1.93 (-1.19%) ▼|MO74.21+1.18 (+1.62%) ▲|MRK127.50-0.13 (-0.10%) ▼|MS215.50-2.87 (-1.31%) ▼|MSFT393.82-7.28 (-1.82%) ▼|MU848.95-4.25 (-0.50%) ▼|NEE88.80-0.55 (-0.62%) ▼|NFLX68.95-5.40 (-7.26%) ▼|NKE43.76-0.81 (-1.82%) ▼|NOW103.24-0.77 (-0.74%) ▼|NVDA202.81-4.59 (-2.21%) ▼|ORCL126.41+2.20 (+1.77%) ▲|PEP137.12-2.31 (-1.66%) ▼|PFE25.05-0.09 (-0.36%) ▼|PG149.98-1.52 (-1.00%) ▼|PLTR132.38-2.06 (-1.53%) ▼|PM192.98+3.14 (+1.65%) ▲|QCOM171.78+1.11 (+0.65%) ▲|RTX193.51-0.85 (-0.44%) ▼|SBUX105.49-2.88 (-2.66%) ▼|SCHW101.56-1.24 (-1.21%) ▼|SO95.30-0.77 (-0.80%) ▼|SPG228.70+0.21 (+0.09%) ▲|T21.81-0.17 (-0.77%) ▼|TMO532.48-10.71 (-1.97%) ▼|TMUS192.43-0.42 (-0.22%) ▼|TSLA380.84-10.22 (-2.61%) ▼|TXN284.02-7.20 (-2.47%) ▼|UBER72.46-1.58 (-2.13%) ▼|UNH426.09+2.71 (+0.64%) ▲|UNP301.75+2.33 (+0.78%) ▲|UPS117.72+0.54 (+0.46%) ▲|USB63.14-0.87 (-1.36%) ▼|V358.56-6.58 (-1.80%) ▼|VZ43.59-0.29 (-0.66%) ▼|WFC87.51-0.56 (-0.64%) ▼|WMT114.24-0.71 (-0.62%) ▼|XOM147.36+1.41 (+0.97%) ▲|
23.7 C
New York
Saturday, July 18, 2026

Tag: medicine

Catherine Hershey Schools for Early Learning Opens First Lancaster County Center

LANCASTER, Pa., July 14, 2026 /PRNewswire/ -- Catherine Hershey Schools for Early Learning (CHS), a subsidiary of Milton Hershey School (MHS), celebrated the grand...

Has Anyone Tried Gundry MD Phyto Collagen Complex? Read Real Reviews, Ingredients, and Benefits

Plant-Based Collagen Support Designed to Help You Feel Stronger, Look Younger, and Move More FreelyLOS ANGELES, July 14, 2026 /PRNewswire/ -- While many collagen powders...

Cardiovascular Logistics Names Dr. Gary Kirsh Chief Executive Officer

Veteran physician executive and former Solaris Health CEO to lead one of the nation's largest cardiology platformsNASHVILLE, Tenn., July 14, 2026 /PRNewswire/ -- Cardiovascular...

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitisFRIENDSWOOD, Texas, July 14,...

Canada takes action to advance a stronger grid and increase reliable, affordable energy

YELLOWKNIFE, NT, June 26, 2026 /CNW/ - The world is changing rapidly: global trade has been upended, artificial intelligence is scaling at speed, and...

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited (“Best Praise”), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Daniel D. King, DNP, Selected as a Fellow of the American Academy of Nursing

NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- Daniel D. King, DNP, CRNA, CPPS, CNE, FNAP, associate professor in the Nurse Anesthesia Program at Rosalind...

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade...

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101

The Inner Circle acknowledges Dr. Barbara Betancourt Cortes as a Pinnacle Lifetime Member

ROSWELL, Ga., June 26, 2026 /PRNewswire/ -- Dr. Barbara Betancourt Cortes is Recognized as a Pinnacle Lifetime Member for Excellence in Chiropractic Care and...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine